litlas
Log inCreate account

Wim van den Brink

Active 1990–2025

200
Papers
29,222
Citations
103
h-index
195
i10-index

Citations

Citations per year for Wim van den Brink1954: 1 citations1962: 1 citations1978: 1 citations1982: 1 citations1992: 4 citations1993: 5 citations1994: 3 citations1995: 11 citations1996: 2 citations1997: 11 citations1998: 6 citations1999: 9 citations2000: 19 citations2001: 31 citations2002: 43 citations2003: 61 citations2004: 99 citations2005: 95 citations2006: 137 citations2007: 133 citations2008: 146 citations2009: 190 citations2010: 173 citations2011: 220 citations2012: 202 citations2013: 324 citations2014: 298 citations2015: 241 citations2016: 215 citations2017: 214 citations2018: 213 citations2019: 773 citations2020: 848 citations2021: 700 citations2022: 510 citations2023: 432 citations2024: 662 citations2025: 244 citations2026: 9 citations1955–1961: no citations, so these years are not shown1963–1977: no citations, so these years are not shown1979–1981: no citations, so these years are not shown1983–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,589 citing papers, 27.3% of this breakdownUnited Kingdom: 962 citing papers, 10.2% of this breakdownCanada: 657 citing papers, 6.9% of this breakdownNetherlands: 643 citing papers, 6.8% of this breakdownGermany: 611 citing papers, 6.4% of this breakdownAustralia: 503 citing papers, 5.3% of this breakdownItaly: 308 citing papers, 3.2% of this breakdownSpain: 277 citing papers, 2.9% of this breakdownChina: 255 citing papers, 2.7% of this breakdownFrance: 253 citing papers, 2.7% of this breakdownSwitzerland: 214 citing papers, 2.3% of this breakdownSweden: 196 citing papers, 2.1% of this breakdown
0%27.3%Other 21.2%

Institutions

Fields

  • Medicine49.1%
  • Psychology21%
  • Neuroscience19.6%
  • Pharmacology, Toxicology and Pharmaceutics3.9%
  • Biochemistry, Genetics and Molecular Biology1.9%
  • Social Sciences1.7%
  • Other2.8%

Topics

  • Substance Abuse Treatment and Outcomes7.1%
  • Neurotransmitter Receptor Influence on Behavior7.1%
  • Cannabis and Cannabinoid Research5.3%
  • Attention Deficit Hyperactivity Disorder3.7%
  • Opioid Use Disorder Treatment3.5%
  • Neural and Behavioral Psychology Studies3.3%
  • Other70%

Coauthors

All papers

Open in search
  1. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder

    Authors: Stephen V. Faraone, Tobias Banaschewski, David Coghill, Yi Zheng, Joseph Biederman, Mark A. Bellgrove, Jeffrey H. Newcorn, Martin Gignac, Nouf Mohammed Al Saud, Iris Manor, Luís Augusto Rohde, Li Yang, Samuele Cortese, Doron Almagor, Mark A. Stein, Turki H. Albatti, Haya F. Al-Joudi, Mohammed M. J. Alqahtani, Philip Asherson, Lukoye Atwoli, Sven Bölte, Jan K. Buitelaar, Cleo L. Crunelle, David Daley, Søren Dalsgaard, Manfred Döpfner, Stacey D. Espinet, Michael Fitzgerald, Barbara Franke, Manfred Gerlach, Jan Haavik, Catharina A. Hartman, Cynthia M. Hartung, Stephen P. Hinshaw, Pieter J. Hoekstra, Chris Hollis, Scott H. Kollins, J. J. Sandra Kooij, Jonna Kuntsi, Henrik Larsson, Tingyu Li, Jing Liu, Eugene Merzon, Gregory W. Mattingly, Paulo Mattos, Suzanne McCarthy, Amori Yee Mikami, Brooke S. G. Molina, Joel T. Nigg, Diane Purper‐Ouakil, Olayinka Omigbodun, Guilherme V. Polanczyk, Yehuda Pollak, Alison Poulton, Ravi Philip Rajkumar, Andrew Reding, Andreas Reif, Katya Rubia, Julia J. Rucklidge, Marcel Romanos, Josep Antoni Ramos‐Quiroga, Arnt Schellekens, Anouk Scheres, Renata Schoeman, Julie B. Schweitzer, Henal Shah, Mary V. Solanto, Edmund Sonuga‐Barke, César A. Soutullo, Hans-Christoph Steinhausen, James M. Swanson, Anita Thapar, Gail Tripp, Geurt van de Glind, Wim van den Brink, Saskia Van der Oord, André Venter, Benedetto Vitiello, Susanne Walitza, Yufeng Wang - Neuroscience & Biobehavioral Reviews 2021 cited by 1,392

  2. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

    Authors: Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, Wim van den Brink, Eric Vermetten, Robert A. Schoevers - Journal of Psychopharmacology 2022 cited by 169

  3. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study

    Authors: Tara Gomes, David N. Juurlink, Tony Antoniou, Muhammad Mamdani, J. Michael Paterson, Wim van den Brink - PLoS Medicine 2017 cited by 528

  4. Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018

    Authors: Mimi Pierce, Jan van Amsterdam, Gerard A. Kalkman, Arnt Schellekens, Wim van den Brink - European Psychiatry 2021 cited by 133

  5. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review

    Authors: Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Wim van den Brink, Robert A. Schoevers - Psychopharmacology 2021 cited by 157

  6. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations

    Authors: Benedikt Fischer, Cayley Russell, Pamela Sabioni, Wim van den Brink, Bernard Le Foll, Wayne Hall, Jürgen Rehm, Robin Room - American Journal of Public Health 2017 cited by 435

  7. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update

    Authors: Benedikt Fischer, Tessa Robinson, Chris Bullen, Valerie H. Curran, Didier Jutras‐Aswad, María Elena Medina‐Mora, Rosalie Liccardo Pacula, Jürgen Rehm, Robin Room, Wim van den Brink, Wayne Hall - International Journal of Drug Policy 2021 cited by 219

  8. Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder

    Authors: Martijn Figee, Judy Luigjes, Ruud Smolders, Carlos-Eduardo Valencia-Alfonso, Guido van Wingen, Bart de Kwaasteniet, Mariska Mantione, Pieter Ooms, Pelle de Koning, Nienke Vulink, Nina Levar, Lukas Droge, Pepijn van den Munckhof, P. Richard Schuurman, Aart J. Nederveen, Wim van den Brink, Ali Mazaheri, Matthijs Vink, Damiaan Denys - Nature Neuroscience 2013 cited by 472

  9. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction

    Authors: John Strang, Teodora Groshkova, Ambros Uchtenhagen, Wim van den Brink, Christian Haasen, Martin T. Schechter, Nick Lintzeris, James Bell, Alessandro Pirona, Eugenia Oviedo‐Joekes, Roland Simon, Nicola Metrebian - The British Journal of Psychiatry 2015 cited by 264

  10. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis

    Authors: Katelijne van Emmerik‐van Oortmerssen, Geurt van de Glind, Wim van den Brink, Filip Smit, Cleo L. Crunelle, Marije Swets, Robert A. Schoevers - Drug and Alcohol Dependence 2011 cited by 533

  11. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence

    Authors: Antoni Gual, Yuan He, Lars Torup, Wim van den Brink, Karl Mann - European Neuropsychopharmacology 2013 cited by 401

  12. Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients

    Authors: Zsuzsika Sjoerds, S de Wit, Wim van den Brink, Trevor W. Robbins, Aartjan T.F. Beekman, Brenda W.J.H. Penninx, Dick J. Veltman - Translational Psychiatry 2013 cited by 320

  13. Decision making in pathological gambling: A comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls

    Authors: Anna E. Goudriaan, Jaap Oosterlaan, Edwin de Beurs, Wim van den Brink - Cognitive Brain Research 2005 cited by 448

  14. Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R Study

    Authors: Hanan El Marroun, Henning Tiemeier, Eric A.P. Steegers, Vincent W. V. Jaddoe, Albert Hofman, Frank C. Verhulst, Wim van den Brink, Anja C. Huizink - Journal of the American Academy of Child & Adolescent Psychiatry 2009 cited by 326

  15. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study

    Authors: Gerard A. Kalkman, Cornelis Kramers, Robert T. van Dongen, Wim van den Brink, Arnt Schellekens - The Lancet Public Health 2019 cited by 200

  16. Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls

    Authors: Hanan El Marroun, James J. Hudziak, Henning Tiemeier, Hanneke E. Creemers, Eric A.P. Steegers, Vincent W. V. Jaddoe, Albert Hofman, Frank C. Verhulst, Wim van den Brink, Anja C. Huizink - Drug and Alcohol Dependence 2011 cited by 153

  17. The therapeutic potential of psilocybin: a systematic review

    Authors: Jan van Amsterdam, Wim van den Brink - Expert Opinion on Drug Safety 2022 cited by 74

  18. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

    Authors: Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, T.L. Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert A. Schoevers - Scientific Reports 2024 cited by 47

  19. A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study

    Authors: Murat Yücel, Erin Oldenhof, Serge H. Ahmed, David Belin, Joël Billieux, Henrietta Bowden‐Jones, Adrian Carter, Samuel R. Chamberlain, Luke Clark, Jason P. Connor, Mark Daglish, Geert Dom, Pinhas N. Dannon, Theodora Duka, María José Fernández-Serrano, Matt Field, Ingmar H. A. Franken, Rita Z. Goldstein, Raúl González, Anna E. Goudriaan, Jon E. Grant, Matthew J. Gullo, Robert Hester, David C. Hodgins, Bernard Le Foll, Rico S. C. Lee, Anne Lingford‐Hughes, Valentina Lorenzetti, Scott J. Moeller, Marcus R. Munafò, Brian L. Odlaug, Marc N. Potenza, Rebecca Segrave, Zsuzsika Sjoerds, Nadia Solowij, Wim van den Brink, Ruth J. van Holst, Valerie Voon, Reínout W. Wiers, Leonardo F. Fontenelle, Antonio Verdejo‐García - Addiction 2018 cited by 236

  20. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis

    Authors: Mimi Pierce, Arjen L. Sutterland, Esther M. Beraha, Kirsten C. Morley, Wim van den Brink - European Neuropsychopharmacology 2018 cited by 161

  21. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective

    Authors: Renaud de Beaurepaire, Julia Sinclair, Mathis Heydtmann, Giovanni Addolorato, Henri‐Jean Aubin, Esther M. Beraha, Fabio Caputo, Jonathan Chick, Patrick de La Selle, Nicolas Franchitto, James C. Garbutt, Paul Haber, Philippe Jaury, Anne Lingford‐Hughes, Kirsten C. Morley, Christian A. Mueller, Lynn Owens, Adam Pastor, Louise M. Paterson, Fanny Pélissier, Benjamin Rolland, Amanda Stafford, Andrew Thompson, Wim van den Brink, Lorenzo Leggio, Roberta Agabio - Frontiers in Psychiatry 2019 cited by 92

  22. Recreational nitrous oxide use: Prevalence and risks

    Authors: Jan van Amsterdam, Ton Nabben, Wim van den Brink - Regulatory Toxicology and Pharmacology 2015 cited by 232

  23. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement

    Authors: Roberta Agabio, Julia Sinclair, Giovanni Addolorato, Henri‐Jean Aubin, Esther M. Beraha, Fabio Caputo, Jonathan Chick, Patrick de La Selle, Nicolas Franchitto, James C. Garbutt, Paul Haber, Mathis Heydtmann, Philippe Jaury, Anne Lingford‐Hughes, Kirsten C. Morley, Christian Müller, Lynn Owens, Adam Pastor, Louise M. Paterson, Fanny Pélissier, Benjamin Rolland, Amanda Stafford, Andrew Thompson, Wim van den Brink, Renaud de Beaurepaire, Lorenzo Leggio - The Lancet Psychiatry 2018 cited by 134

  24. Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study

    Authors: Jentien M. Vermeulen, Robyn E. Wootton, Jorien L. Treur, Hannah Sallis, Hannah Jones, Stanley Zammit, Wim van den Brink, Guy M. Goodwin, Lieuwe de Haan, Marcus R. Munafò - The British Journal of Psychiatry 2019 cited by 79